Verastem

formerly Verastem OncologyIPO

Precision targeting of RAS/MAPK pathway-driven cancers

Public · Boston, United States · Founded 2010 · $392.5M raised

Employees
51–200
Founded
2010
Business Model
B2B
Total Funding
$392.5M
Last Round
$90.0M Corporate RoundNov 2025
Rounds
8
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Verastem Oncology is a biopharmaceutical company focused on developing and commercializing medicines to improve the lives of patients with cancer. The company's pipeline targets the RAS/MAPK signaling pathway, which drives cell survival and tumor growth, through novel small molecule inhibitors. This includes KRAS G12D inhibition, RAF/MEK inhibition, and FAK inhibition to address resistance mechanisms. Verastem achieved an FDA-approved treatment (AVMAPKI FAKZYNJA CO-PACK) for KRAS-mutant recurrent low-grade serous ovarian cancer, the first approved therapy for this indication. The company trades on NASDAQ under the symbol VSTM.

Summary

Verastem is a Biotech company based in Boston, United States, founded in 2010. It has raised $392.5M in total across 8 rounds, most recently a $90.0M Corporate Round in Nov 2025. Investors include Bessemer Venture Partners, Advanced Technology Ventures and MPM Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Corporate RoundCorporate RoundNov 2025
$90.0M

Sign up to see all 10 events

Funding: Series A through Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Verastem on Indexed.vc
<a href="https://indexed.vc/companies/verastem"><img src="https://indexed.vc/api/badge/company/verastem" alt="Verastem on Indexed.vc" width="260" height="76" /></a>